572 related articles for article (PubMed ID: 28359278)
1. Review of 11 national policies for rare diseases in the context of key patient needs.
Dharssi S; Wong-Rieger D; Harold M; Terry S
Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
[TBL] [Abstract][Full Text] [Related]
2. Tackling rare diseases at European level: why do we need a harmonized framework?
Taruscio D; Trama A; Stefanov R
Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
[TBL] [Abstract][Full Text] [Related]
3. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
4. Intractable and rare diseases research in Asia.
Song P; Gao J; Inagaki Y; Kokudo N; Tang W
Biosci Trends; 2012 Apr; 6(2):48-51. PubMed ID: 22621985
[TBL] [Abstract][Full Text] [Related]
5. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
6. Orphan drugs: the regulatory environment.
Franco P
Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
[TBL] [Abstract][Full Text] [Related]
7. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
8. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
9. [The legal regulation of life cycle of orphan pharmaceuticals].
Gildeyeva GN; Kartavtsova TV
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
[TBL] [Abstract][Full Text] [Related]
10. A civil society view of rare disease public policy in six Latin American countries.
Mayrides M; Ruiz de Castilla EM; Szelepski S
Orphanet J Rare Dis; 2020 Feb; 15(1):60. PubMed ID: 32106873
[TBL] [Abstract][Full Text] [Related]
11. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
Herder M
Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
[TBL] [Abstract][Full Text] [Related]
12. History of Orphan Drug Regulation-United States and Beyond.
Haffner ME
Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
[TBL] [Abstract][Full Text] [Related]
13. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
[TBL] [Abstract][Full Text] [Related]
14. Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey.
Thrift-Perry M; Cabanes A; Cardoso F; Hunt KM; Cruz TA; Faircloth K
Breast; 2018 Oct; 41():93-106. PubMed ID: 30025274
[TBL] [Abstract][Full Text] [Related]
15. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
[TBL] [Abstract][Full Text] [Related]
17. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical policy and innovation for rare diseases: A narrative review.
Alonso Ruiz A; Large K; Moon S; Vieira M
F1000Res; 2023; 12():211. PubMed ID: 38778810
[TBL] [Abstract][Full Text] [Related]
19. Health care policy. Reforming off-label promotion to enhance orphan disease treatment.
Liang BA; Mackey T
Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234
[No Abstract] [Full Text] [Related]
20. [Hungarian national plan and strategy for rare diseases].
Kosztolányi G
Orv Hetil; 2014 Mar; 155(9):325-8. PubMed ID: 24566695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]